NewsBenzingaTakeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis Benzinga 2026.09.30 06:52 (GMT+0) Open on Benzinga Other news ANT, NVDA, PANW and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week Benzinga's 'Stock Whisper' Index: Five Stocks Investors Secretly Monitor But Don't Talk About Yet Consumer Tech (Nov 16-20): Anthropic Makes A Smashing Debut, GTA 6 Releases & More BTCS Warns of Liquidation Risk on $54M Aave Debt Larry McDonald survived Lehman’s collapse. Now he warns the credit market is signaling a growth shock for stocks. How a brutal week for stocks almost wiped out their gains for the entire year
Larry McDonald survived Lehman’s collapse. Now he warns the credit market is signaling a growth shock for stocks.